# Neuromuscular Neurology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Mankiller (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML052-SYN-TD
- Date: 1980-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rena Hawkfeather-Lindqvist, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Marcus Okafor-Delaney, MD, Neuromuscular Neurology
- Urgency: Urgent, within two weeks

## Referral question

Woman of 34 with six weeks of fluctuating ptosis, diplopia and fatigable weakness of the arms, neck, chewing and voice, while recovering from a severe car crash last year: suspected generalized myasthenia gravis. Please confirm the diagnosis and advise on treatment, thymectomy and safety. **S**

## Questions for the consultant

1. Do you agree with the diagnosis, and are MuSK antibodies or single-fiber EMG needed?
2. What pyridostigmine dose, and how should immunotherapy begin?
3. Which steroid-sparing agent suits a woman of 34 with polycystic kidney disease, and what screening is needed first?
4. Should she have a thymectomy, and when, so soon after major trauma?
5. Is there a place now for newer targeted therapies such as efgartigimod or eculizumab?
6. What should she and primary care watch for: crisis warning signs, medicines to avoid, and any kidney considerations?

## Pertinent history

Cherokee Nation citizen living in rural Adair County, about an hour's drive from this clinic; works for the Cherokee Nation. Head-on car crash last year with fractures of both legs, ribs and face and many operations; walks independently, with a cane on rough ground. Hereditary polycystic kidney disease, as she has described it, with normal kidney function. Examination: left-predominant ptosis after 30 seconds of upgaze, improved by 3 mm after a two-minute ice pack; diplopia on sustained lateral gaze; neck flexion 4 of 5; deltoids fatigue after 30 seconds; nasal voice after counting to 30; reflexes and sensation normal. FVC 3.30 L, negative inspiratory force -70 cm H2O, single-breath count 32. Blood count, chemistry and TSH normal; creatinine 0.78 mg/dL, eGFR 102, urine albumin 14 mg/g; hemoglobin A1c 5.3 percent. PHQ-9 score 7. Acetylcholine receptor antibodies sent; chest CT with contrast and kidney ultrasound booked. Pyridostigmine 30 mg three times daily started as a trial. No other regular medicines except acetaminophen. She would like blood tests near home where possible and her own Cherokee medicine respected. **S**

- Wilma Pearl Mankiller was born on November 18, 1945, in Tahlequah, Oklahoma, the capital of the Cherokee Nation, the sixth of eleven children; her father was a full-blood Cherokee. A Cherokee Nation release gave her birthplace as the W.W. Hastings Indian Hospital in Tahlequah; the Oklahoma Hall of Fame says she was born at Rock Mountain in Adair County. **D**
- As a child she moved with her family from Mankiller Flats in Adair County to San Francisco under the Bureau of Indian Affairs relocation program (1956 or 1957 by different accounts); she later described the move as her own little Trail of Tears. **D**
- The occupation of Alcatraz Island in 1969 and her work with American Indian communities in California in the 1970s set the course of her activism. **D**
- She returned to eastern Oklahoma with her two daughters in the later 1970s (1976 or 1977 by different accounts), worked for the Cherokee Nation, and lived on her grandfather's allotment, Mankiller Flats, in Adair County. **D**
- In 1979 she was nearly killed in a head-on car crash on a curve, in which the driver of the other car, one of her best friends, died. She needed about 17 operations; accounts say her leg was barely saved from amputation and that she was told she might never walk again. The Oklahoma Hall of Fame dates the crash to 1978 and describes shattered legs, broken ribs and a crushed face. **D**
- Her recovery was made harder by the emotional trauma of her friend's death in the crash. **D**

8 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Hemoglobin: 12.8 g/dL; White cell count: 6.9 10*3/uL; Platelets: 262 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.2 mmol/L; Glucose: 88 mg/dL; Creatinine: 0.78 mg/dL; eGFR (CKD-EPI 1975): 102 mL/min/1.73 m²; Calcium: 9.4 mg/dL; ALT: 18 U/L; AST: 21 U/L; Albumin: 4.2 g/dL; TSH: 1.9 mIU/L; Hemoglobin A1c: 5.3%; Urine albumin-to-creatinine ratio: 14 mg/g; 25-hydroxyvitamin D: 31 ng/mL; Forced vital capacity (seated): 3.3 L; PHQ-9: 7. All results are synthetic.

BP 126/82 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 61.8 kg; BMI 23.3 kg/m². All vital signs are synthetic.

## Current medications

- Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating **S**
- Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain **S**

## Plan so far

- Diagnostic tests: acetylcholine receptor binding antibodies (MuSK antibodies if negative), repetitive nerve stimulation (single-fiber EMG if unclear), CT of the chest with contrast for thymoma, TSH, and seated FVC with negative inspiratory force. Guideline: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016) **S**
- Safety: pyridostigmine 30 mg three times daily as a trial; warning signs of myasthenic crisis (breathlessness lying flat, weak cough, trouble swallowing, slurred speech) with emergency care the same day; a wallet card and the list of medicines to avoid, including fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers and telithromycin. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026) **S**
- Kidney care for her hereditary polycystic kidney disease: kidney ultrasound with total kidney volume, eGFR and urine albumin, home blood pressure readings, 2 to 3 liters of water a day spread through the day, less salt, and acetaminophen instead of NSAIDs. Guideline: KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025) **S**
- Culturally safe care: laboratory work at a Cherokee Nation Health Services clinic near her home, results shared with this clinic; time given to explain each test and medicine plainly; her own Cherokee medicine respected, with any plant medicine shared so that interactions can be checked, and nothing further asked. Guideline: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cherokee Nation Health Services (2026) **S**
